Marker Therapeutics (Houston, TX) is advancing a novel treatment (MT-601) derived from the patient's own immune system. The objective is to enhance the clinical response of patients with metastatic pancreatic cancer (mPC). This process begins by isolating the patient's immune cells (lymphocytes) from their own blood, and then training these cells in the laboratory to recognize hundreds of independent targets on the tumor cells. These cells are then infused back into the patient in an outpatient setting, thus allowing the patient's own immune system to attack the cancer cells. In this study, we are advancing MT-601 in patients with mPC by combining it with currently available standard of care...

Read More

Marker Therapeutics (Houston, TX) is advancing a novel treatment (MT-601) derived from the patient's own immune system. The objective is to enhance the clinical response of patients with metastatic pancreatic cancer (mPC). This process begins by isolating the patient's immune cells (lymphocytes) from their own blood, and then training these cells in the laboratory to recognize hundreds of independent targets on the tumor cells. These cells are then infused back into the patient in an outpatient setting, thus allowing the patient's own immune system to attack the cancer cells. In this study, we are advancing MT-601 in patients with mPC by combining it with currently available standard of care chemotherapy (FOLFIRINOX). We anticipate that the combination of these treatments will improve the clinical outcomes of these patients over chemotherapy alone. We believe this study will be successful for several reasons: 1) the FDA has approved the proposed study testing the combination of MT-601 with chemotherapy in mPC; 2) we are already manufacturing MT-601 for another clinical study, where it is showing promising clinical responses and no toxicities to date; and 3) we have already demonstrated proof-of-concept in mPC using our therapy, which was well-tolerated and provided clinical benefit. Because MT-601 uses the patients' own immune system to help fight the cancer, it can be safely combined with chemotherapy to enhance patient responses, which is the main goal of this study.

Read Less